A safer, more reliable source of medical isotopes—made in the U.S., helping patients worldwide.
Millions of patients depend on medical isotopes for life-saving scans and cancer treatments. Yet most of the world’s supply still comes from a handful of overseas reactors. Many are more than 60 years old and prone to outages. When these fail, patients wait. Delays can mean the difference between life and death.
We’re building a new path forward. Today, we’re supplying U.S.-made isotopes. At the same time, we’re developing the capability to produce these isotopes using fusion technology. This means a steady supply for providers and researchers now—and an end to chronic shortages in the years ahead.
Theranostics unites diagnosis and treatment. Providers first use a radioactive isotope to see where disease is. Then, often with the very same isotope, they treat those tumors directly. This dual approach is transforming cancer care, offering more precise detection and more targeted therapies.
At the center of this breakthrough is lutetium-177. When paired with a cancer-seeking drug, this medical isotope delivers radiation directly to tumors while sparing nearby tissue. Global demand for Lu-177 is soaring, but supply has been unstable—and most of it is lower in purity.
Our answer is Cassiopeia, one of the largest Lu-177 production facilities in North America. From here we produce Ilumira, our ≥99.9% pure Lu-177 chloride. We’re not only giving patients and physicians a reliable U.S. source, but we’re also building the capacity to meet demand around the world.
These milestones trace the progress of our medical isotopes journey:
%20(5).jpg)
Molybdenum-99 (Mo-99) is essential for diagnostic imaging because it decays into technetium-99m (Tc-99m). This is the isotope that typically powers SPECT, the most widely used form of nuclear imaging. Tc-99m enables more than 40 million scans each year, helping providers detect cancer, heart disease, and other serious conditions early.
Yet Mo-99 production remains entirely overseas, with limited capacity to meet demand.
We’re solving this challenge with the construction of Chrysalis, the world’s largest medical isotope production facility. Built for scale, it will supply up to 20 million doses of Mo-99 a year and create a reliable U.S. source for a worldwide market.
Chrysalis is engineered with hardened safety systems and redundant production vaults to achieve continuous supply. To reliably move isotopes from plant to patient, we’re also planning vertical integration so providers get a sturdier, U.S.-based supply chain.
